Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | PKM | P14618 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557193 | 0.87 | ALDH1A1 (0.84) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL10726712 | 0.87 | ALDH1A1 (0.84) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL12582715 | 0.85 | BLM (0.71) | BLMALDH1A1PKMHPGDMEN1 | |
| SCHEMBL7838280 | 0.85 | BLM (0.71) | BLMHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7838912 | 0.85 | BLM (0.71) | BLMALDH1A1HPGDKMT2ALMNA | |
| SCHEMBL16098566 | 0.85 | BLM (0.71) | BLMALDH1A1HPGDHTTKMT2A | |
| Sunifiram SCHEMBL195641 | 0.84 | BLM (1.00) | BLMALDH1A1HPGDUSP2MEN1 | |
| SCHEMBL12582727 | 0.83 | PKM (0.62) | BLMALDH1A1PKMHPGDUSP2 | |
| SCHEMBL10195012 | 0.83 | ALDH1A1 (0.72) | ALDH1A1PKMHPGDUSP2MEN1 | |
| SCHEMBL7846247 | 0.82 | HPGD (0.69) | BLMALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1118612-A1 | Piperazine derivatives possesing nootropic activity | Universita Degli Studi di Firenze (IT) | 2001-07-25 | — | — | EP | claimed |
| US-9175061-B2 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20110144017-A1 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| EP-1118612-A1 | Piperazine derivatives possesing nootropic activity | Universita Degli Studi di Firenze (IT) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144017-A1 | Protein conjugates and methods for their preparation | PTMS, DNPEP, ANPEP | BLM 3574/4885ALDH1A1 256/4885PKM 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.